Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. (CMOPF) Revenue
Annual & quarterly revenue history · segment & region breakdown
CMOPF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCosmo Pharmaceuticals N.V. trailing twelve-month (TTM) revenue is $0.37B, a decrease of 60.71% year-over-year from $0.10B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.10B | -$0.16B | -60.71% |
| 2024-12-31 | $0.27B | +$0.17B | +187.55% |
| 2023-12-31 | $0.09B | -$0.01B | -9.12% |
| 2022-12-31 | $0.10B | +$0.04B | +56.88% |
| 2021-12-31 | $0.07B | +$0.00B | +6.77% |
| 2020-12-31 | $0.06B | -$0.00B | -2.47% |
| 2019-12-31 | $0.06B | -$0.00B | -4.76% |
| 2018-12-31 | $0.07B | -$0.00B | -2.42% |
| 2017-12-31 | $0.07B | -$0.00B | -0.62% |
| 2016-12-31 | $0.07B | +$0.01B | +11.64% |
Compare revenue vs peers
Drug Manufacturers - Specialty & GenericCompare CMOPF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Cosmo Pharmaceuticals N.V. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Cosmo Pharmaceuticals N.V. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Cosmo Pharmaceuticals N.V.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CMOPF revenue · 4 questionsCMOPF's trailing twelve-month (TTM) revenue is $0.37B. That is a decrease of 60.71% year-over-year from $0.10B in FY2025.
▸ Source: FMP · Cosmo Pharmaceuticals N.V. SEC filings · GAAP · Cosmo Pharmaceuticals N.V. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026